US20050131513A1 - Stent catheter with a permanently affixed conductor - Google Patents
Stent catheter with a permanently affixed conductor Download PDFInfo
- Publication number
- US20050131513A1 US20050131513A1 US10/738,812 US73881203A US2005131513A1 US 20050131513 A1 US20050131513 A1 US 20050131513A1 US 73881203 A US73881203 A US 73881203A US 2005131513 A1 US2005131513 A1 US 2005131513A1
- Authority
- US
- United States
- Prior art keywords
- stent
- conductor
- catheter
- balloon
- assembly according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000004020 conductor Substances 0.000 title claims abstract description 59
- 238000000576 coating method Methods 0.000 claims abstract description 59
- 239000011248 coating agent Substances 0.000 claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 34
- 239000003814 drug Substances 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 23
- 239000000463 material Substances 0.000 claims description 9
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 6
- 238000007649 pad printing Methods 0.000 claims description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052737 gold Inorganic materials 0.000 claims description 3
- 239000010931 gold Substances 0.000 claims description 3
- 229910052697 platinum Inorganic materials 0.000 claims description 3
- 229910052709 silver Inorganic materials 0.000 claims description 3
- 239000004332 silver Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 abstract description 13
- 238000009503 electrostatic coating Methods 0.000 abstract description 9
- 230000008901 benefit Effects 0.000 description 16
- 238000002399 angioplasty Methods 0.000 description 13
- 239000000976 ink Substances 0.000 description 13
- 208000037803 restenosis Diseases 0.000 description 12
- 210000004351 coronary vessel Anatomy 0.000 description 7
- 229910052751 metal Inorganic materials 0.000 description 7
- 239000002184 metal Substances 0.000 description 7
- 208000014674 injury Diseases 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 230000002093 peripheral effect Effects 0.000 description 6
- 230000008733 trauma Effects 0.000 description 6
- 238000013459 approach Methods 0.000 description 4
- 206010020718 hyperplasia Diseases 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 201000000057 Coronary Stenosis Diseases 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 238000010422 painting Methods 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 239000004593 Epoxy Substances 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910001000 nickel titanium Inorganic materials 0.000 description 2
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 239000010963 304 stainless steel Substances 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229910000589 SAE 304 stainless steel Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920001940 conductive polymer Polymers 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007641 inkjet printing Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012781 shape memory material Substances 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/95—Instruments specially adapted for placement or removal of stents or stent-grafts
- A61F2/958—Inflatable balloons for placing stents or stent-grafts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/082—Inorganic materials
- A61L31/088—Other specific inorganic materials not covered by A61L31/084 or A61L31/086
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
Definitions
- the present invention relates generally to medical devices and particularly to a catheter used to implant stents which has a permanently affixed conductor.
- stents to treat various organs, such as the vascular system, colon, biliary tract, urinary tract, esophagus, trachea and the like, has become common.
- stents are useful in treating blockages, occlusions, narrowing ailments and other similar problems that restrict flow through a passageway.
- Stents are useful for numerous medical treatments of various vessels throughout the vascular system, including both coronary vessels and peripheral vessels (e.g., carotid, brachial, renal, iliac and femoral).
- coronary vessels e.g., carotid, brachial, renal, iliac and femoral
- peripheral vessels e.g., carotid, brachial, renal, iliac and femoral.
- stents in coronary vessels has drawn particular attention from the medical community due to the commonality of heart problems caused by stenosis (i.e., narrowing of a vessel).
- stenosis may occur for a variety of reasons, one of the most common causes of coronary stenosis results from the buildup of atherosclerotic plaques along the lumen of the vessel. The resulting coronary stenosis restricts blood flow through the vessel, which eventually can lead to a dangerously increased risk of heart attacks.
- PTA percutaneous transluminal angioplasty
- restenosis i.e., re-narrowing
- Restenosis may occur for a variety of reasons, such as collapsing of the vessel wall or growth of cellular tissue.
- restenosis may occur due to damage caused to the vessel lining during balloon expansion and vessel dilating.
- the vessel attempts to grow new intima tissue to repair the damage.
- This tendency of vessels to regrow new tissue is referred to as neointimal hyperplasia.
- the effect of this response results in a re-narrowing of the vessel.
- restenosis is not completely predictable and may occur either abruptly soon after the PTA procedure due to vessel collapse or may occur slowly over a longer period of time due to other reasons.
- stents are made of metal or other synthetic materials, thereby providing a tubular support structure that radially supports the inner wall of the vessel.
- stainless steel e.g., 316L SS and 304 SS
- Nitinol e.g., 316L SS and 304 SS
- stents are designed with a pattern of openings formed in the support structure that permits the stent to radially expand from a small diameter to a larger diameter.
- stents are now commonly used in conjunction with conventional PTA procedures by positioning the stent within the portion of the vessel that has been dilated by the balloon and radially expanding the stent against the inner wall of the vessel to permanently implant the stent.
- the expectation of this revised PTA procedure is that the support structure of the implanted stent will mechanically prevent the vessel from collapsing back to its original narrowed condition.
- Balloon-expandable stents are generally made from ductile materials that plastically deform relatively easily. In the case of stents made from metal, 316L stainless steel that has been annealed is a common choice for this type of stent.
- One common procedure for implanting a balloon-expandable stent involves mounting the stent circumferentially on the balloon prior to threading the balloon-tipped catheter to the narrowed vessel portion that is to be treated. When the balloon is positioned at the narrowed vessel portion and expanded, the balloon simultaneously dilates the vessel and also radially expands the stent into the dilated portion.
- a second common category of stents is referred to as self-expandable stents.
- Self-expandable stents are generally made of shape memory materials that act like a spring. Typical metals used in this type of stent include Nitinol and 304 stainless steel.
- a common procedure for implanting a self-expandable stent involves a two-step process. First, the narrowed vessel is dilated with the balloon as described above. Second, the stent is implanted into the dilated vessel portion. To accomplish the stent implantation, the stent is installed on the end of a catheter in a compressed, small diameter state and is retained in the small diameter by inserting the stent into the lumen of the catheter or by other means.
- the stent is then guided to the balloon-dilated portion and is released from the catheter and allowed to radially spring outward to an expanded diameter until the stent contacts and presses against the vessel wall.
- self-expandable stents have been more commonly used in peripheral vessels than in coronary vessels due to the shape memory characteristic of the metals used in these stents.
- One advantage of self-expandable stents for peripheral vessels is that traumas from external sources do not permanently deform the stent. Instead, the stent may temporarily deform during an unusually harsh trauma but will spring back to its expanded state once the trauma is relieved.
- Self-expandable stents are often considered to be less preferred for coronary vessels as compared to balloon-expandable stents.
- balloon-expandable stents can be precisely sized to a particular vessel diameter and shape since the ductile metal that is used can be plastically deformed to a desired size and shape.
- self-expandable stents are designed with a particular expansible range. Thus, after being installed self-expandable stents continue to exert pressure against the vessel wall.
- restenosis still remains a problem.
- one cause of restenosis is neointimal hyperplasia which may result from damage to the vessel wall. This cause of neointimal hyperplasia remains a problem even when a stent is used.
- the synthetic materials that are usually used in stents may also contribute to neointimal hyperplasia. The cause of this problem is the body's tendency to grow new living tissues around and over newly implanted foreign objects. Thus, despite the mechanical support structure provided by the stent, restenosis remains a problem.
- a stent is provided by the manufacturer as part of a pre-assembled package.
- the package may include a catheter, a balloon formed at the end of the catheter, and a drug-coated stent mounted onto the balloon.
- the package may include a catheter, a mounting apparatus for retaining and releasing the stent, and a drug-coated stent mounted on the apparatus.
- One method that may be used to manufacture the above-described stent assemblies involves coating the stent first in a separate step and then mounting the coated stent onto the balloon or other mounting apparatus.
- Common coating processes include dipping, spraying and painting the drug onto the stent.
- these methods suffer from numerous problems.
- One problem is the difficulty of mounting the coated stent onto the catheter without damaging the coating that has been applied.
- many conventional coating processes are difficult to control and apply an uneven coating on the stent.
- the stent may be coated after being mounted onto the catheter.
- this method has not been perfected.
- conventional coating processes are difficult to control and apply uneven coatings. This can be an even more significant problem when the coating is applied to a stent mounted to a catheter since the coating inevitably ends up coating the catheter, balloon and/or mounting apparatus also.
- Precisely controlling the application of coatings on stents is important for a number of reasons. For example, in the case of drug coatings in particular, it is important to ensure that the drug is applied as evenly as possible on the specific surfaces where the coating is needed. This ensures a uniform physiological response to the drug after the stent is implanted. Another important reason for precisely controlling the application of coatings is the high cost of many coatings. Typically, in the case of drug coatings, the cost of the drug per unit volume can be very expensive. Therefore, the drug should be applied as precisely as possible to the surfaces of the stent where the effectiveness of the drug can be maximized. Thus, by minimizing waste during the coating process, the overall cost of the stent assembly may be reduced.
- a stent assembly is provided with a conductor that is permanently affixed to a catheter.
- the conductor is applied to the exterior of the catheter using conductive ink.
- the conductor extends longitudinally along the catheter and contacts the stent.
- One advantage of the conductor is that the stent assembly may be coated with drugs or other coatings using an electrostatic coating process. During the electrostatic coating process, the conductor is grounded or connected to an opposite electrical charge, thereby providing electrical attraction between charged coating particles and the stent. Additional details and advantages are further described below.
- FIG. 1 is a side view of a catheter with a balloon and stent located at a distal end thereof, showing an electrostatic coating process
- FIG. 2 is a close-up side view of a portion of the catheter, showing the balloon and the stent with a conductor extending along a portion thereof.
- a stent assembly 10 is provided for use in percutaneous transluminal angioplasty (“PTA”) procedures.
- the stent assembly 10 is provided as a pre-assembled package with the stent 16 mounted onto a balloon 14 which is formed at the end of a catheter 12 .
- the principles taught herein may also be adapted to a self-expandable stent assembly in which the stent is mounted on a mounting apparatus that selectively retains and releases the stent.
- the catheter 12 includes a conductor 18 that is permanently affixed to the catheter 12 .
- the conductor 18 is affixed to the outer surface of the catheter 12 and extends longitudinally along a portion of the catheter 12 .
- the conductor 18 may extend along the full length of the catheter 12 , or the conductor 18 may extend as little as an inch or less along the catheter 12 .
- the conductor 18 may also extend along a portion of the balloon 14 .
- the conductor 18 contacts an inner surface of the stent 16 . Since the stent 16 is metallic, an electrical connection is made between the stent 16 and the conductor 18 .
- the conductor 18 comprises conductive ink that is applied to the exterior of the catheter 12 and balloon 14 as a stripe.
- conductive ink that may be used is a silver-based epoxy ink. Conductive ink of this type may be obtained from Creative Metals Incorporated as product number CMI 119-21 and referred to as Printable Solvent Resistant Electrically Inductive Ink.
- numerous other types of conductive ink may also be used, such as platinum-based, gold-based and copper-based inks.
- Non-epoxy inks may also be used, such as urethane inks.
- any compound which may be applied in a liquid or gel form and is capable of conducting an electrical current after application may be considered conductive ink.
- the conductor 18 may also comprise any other conductive material, such as conductive polymers.
- the conductive ink may be applied to the catheter 12 and balloon 14 with a variety of printing processes, such as pad printing, ink jet printing, spraying, marker striping, painting or other like processes.
- pad printing is preferred since it is relatively easy with this process to apply a consistent ink stripe on the catheter 12 and balloon 14 .
- An advantage of the conductor 18 is that coatings 24 may be applied to the stent 16 with electrostatic coating processes instead of conventional coating processes.
- an electrostatic spray nozzle 20 charges the coating material and dispenses charged coating particles 22 towards and around the stent 16 .
- Examples of electrostatic coating processes that may be used are described in U.S. Pat. Nos. 4,749,125; 5,165,601; 5,086,973 and 5,332,154, which are all hereby incorporated by reference herein.
- Other electrostatic coating processes may also be used, and any coating process that electrically charges the coating material may be adapted for coating the stent 16 .
- An electrical charge is also applied to the conductor 18 by either grounding the conductor 18 or by connecting the conductor 18 to a charge that is opposite to the charge of the coating particles 22 .
- the charged coating particles 32 become electrically attracted to the stent 16 .
- the coating particles 22 are drawn to the surfaces of the stent 16 and adhere to the stent 16 once contact is made.
- the coating 24 that results is considerably more consistent and uniform than coatings applied by conventional processes.
- the conductor 18 may be grounded 26 in any manner known to those in the art.
- the conductor 18 may be grounded 26 by the fixture that holds the stent assembly 10 during the coating process. Collets or other known arrangements may be readily adapted to serve as a ground 26 for the conductor 18 .
- the conductor 18 may be connected to an opposite charge in any manner known in the art.
- Electrostatic coating offers significant improvements over conventional coating processes, such as dipping, spraying and painting.
- One of the benefits of electrostatic coating is that the application of the coating 24 can be precisely controlled.
- a precise amount of the therapeutic agent can be applied uniformly over the stent 16 without the inconsistencies and waste of conventional processes. This is particularly helpful when typical anti-restenosis drugs are used since these drugs can be especially expensive.
- Other coatings 24 may also be applied to the stent 16 , such as hydrophilic coatings, with similar benefits.
- the stent 16 there are also several advantages of coating the stent 16 after the stent 16 has been mounted to the catheter 16 as compared to separately coating the stent 16 .
- One benefit is that damage to the coating 24 can be minimized since the manufacturer does not need to handle an already coated stent when mounting the stent 16 to the balloon 14 .
- Another benefit is that the coating 24 is applied only to the outside surface of the stent 16 instead of being applied partially to the inside of the stent 16 as may occur when the stent 16 is coated separately. In the case of anti-restenosis drugs, this is a more efficient result since the anti-restenosis drug is primarily needed on the exterior surfaces of the stent 16 where the stent 16 contacts the vessel wall after implantation.
- the electrically charged coating particles 22 will be attracted primarily to the metallic stent 16 as compared to the non-metallic balloon, some of the drug coating 24 (or any other coating used) can be expected to pass through the openings in the stent 16 and adhere to the balloon 14 instead of the stent 16 . However, even these balloon-coated portions may provide some benefits since these coated portions may contact the vessel wall during balloon expansion, thereby being transferred to the vessel wall.
- a further advantage of the conductor 18 is that it is permanently affixed to the catheter 12 .
- One alternative approach that could be used to electrostatically coat a stent 16 involves positioning a loose ground wire under or adjacent the stent 16 to make an electrical connection. However, this approach is undesirable because the loose wire may be inadvertently left attached to the stent assembly 10 after coating. This could have serious consequences if the loose wire is not removed prior to a surgeon using the stent assembly 10 in a PTA procedure. In addition, even when the wire is properly removed during manufacturing of the stent assembly 10 , the removal step could damage the stent assembly 10 . One possible risk is that the wire might puncture the balloon 14 . In addition, removal of the wire may dislodge some of the coating 24 .
- the conductor may also provide other advantages as well.
- the conductor 18 may improve visualization of the catheter 12 and stent assembly 10 during implantation by showing up more distinctly in imaging devices.
- the conductor 18 could be used during PTA or other surgical procedures to supply electrical current to the internal area of the body that is being treated.
Abstract
A stent assembly is provided. A conductor which is permanently affixed to a catheter contacts a stent mounted on the catheter. Conductive ink applied to the catheter may be used as the conductor. A method of coating the stent is also provided. In the method, an electrical charge is applied to the conductor. The stent is then coated using an electrostatic coating process.
Description
- The present invention relates generally to medical devices and particularly to a catheter used to implant stents which has a permanently affixed conductor.
- The use of stents to treat various organs, such as the vascular system, colon, biliary tract, urinary tract, esophagus, trachea and the like, has become common. Typically, stents are useful in treating blockages, occlusions, narrowing ailments and other similar problems that restrict flow through a passageway.
- One common medical treatment in which stents are used involves implanting an endovascular stent into the vascular system. Stents are useful for numerous medical treatments of various vessels throughout the vascular system, including both coronary vessels and peripheral vessels (e.g., carotid, brachial, renal, iliac and femoral). However, the use of stents in coronary vessels has drawn particular attention from the medical community due to the commonality of heart problems caused by stenosis (i.e., narrowing of a vessel).
- Although stenosis may occur for a variety of reasons, one of the most common causes of coronary stenosis results from the buildup of atherosclerotic plaques along the lumen of the vessel. The resulting coronary stenosis restricts blood flow through the vessel, which eventually can lead to a dangerously increased risk of heart attacks.
- The medical community has attempted to address coronary stenosis (along with the many other passageway problems that patients suffer from) with various versions of percutaneous transluminal angioplasty (“PTA”). Fundamentally, PTA involves inserting a balloon-tipped catheter into a vessel and threading the catheter to the narrowed portion to be treated. The balloon is then expanded at the narrowed portion by pumping saline through the catheter to the balloon. As a result, the balloon expands, contacts the inner vessel wall, and forces the vessel to dilate. The balloon is then deflated and retracted from the vessel.
- One problem that has been encountered with typical PTA procedures is restenosis (i.e., re-narrowing) of the vessel. Restenosis may occur for a variety of reasons, such as collapsing of the vessel wall or growth of cellular tissue. For example, restenosis may occur due to damage caused to the vessel lining during balloon expansion and vessel dilating. As a result of the damage caused to the intima layers of the vessel, the vessel attempts to grow new intima tissue to repair the damage. This tendency of vessels to regrow new tissue is referred to as neointimal hyperplasia. The effect of this response results in a re-narrowing of the vessel. However, restenosis is not completely predictable and may occur either abruptly soon after the PTA procedure due to vessel collapse or may occur slowly over a longer period of time due to other reasons.
- One approach the medical community has tried in order to overcome the problems with restenosis is to use stents in conjunction with the above-described PTA procedure. Traditionally, stents are made of metal or other synthetic materials, thereby providing a tubular support structure that radially supports the inner wall of the vessel. Although other materials are possible and are sometimes used, the most common materials now used in stents are stainless steel (e.g., 316L SS and 304 SS) and Nitinol. Typically, stents are designed with a pattern of openings formed in the support structure that permits the stent to radially expand from a small diameter to a larger diameter. Accordingly, stents are now commonly used in conjunction with conventional PTA procedures by positioning the stent within the portion of the vessel that has been dilated by the balloon and radially expanding the stent against the inner wall of the vessel to permanently implant the stent. The expectation of this revised PTA procedure is that the support structure of the implanted stent will mechanically prevent the vessel from collapsing back to its original narrowed condition.
- Although stent designs and implantation procedures vary widely, two categories are common.
- The first of these two categories may be referred to as balloon-expandable stents. Balloon-expandable stents are generally made from ductile materials that plastically deform relatively easily. In the case of stents made from metal, 316L stainless steel that has been annealed is a common choice for this type of stent. One common procedure for implanting a balloon-expandable stent involves mounting the stent circumferentially on the balloon prior to threading the balloon-tipped catheter to the narrowed vessel portion that is to be treated. When the balloon is positioned at the narrowed vessel portion and expanded, the balloon simultaneously dilates the vessel and also radially expands the stent into the dilated portion. The balloon and the catheter are then retracted, leaving the expanded stent permanently implanted at the desired location. Ductile metal lends itself to this type of stent since the stent may be compressed by plastic deformation to a small diameter when mounted onto the balloon. When the balloon is then expanded in the vessel, the stent is once again plastically deformed to a larger diameter to provide the desired radial support structure. Traditionally, balloon-expandable stents have been more commonly used in coronary vessels than in peripheral vessels due to the deformable nature of these stents. One reason for this is that peripheral vessels tend to experience frequent traumas from external sources (e.g., impacts to a person's arms, legs, etc.) which are transmitted through the body's tissues to the vessel. In the case of peripheral vessels, there is an increased risk that an external trauma could cause a balloon-expandable stent to once again plastically deform in unexpected ways with potentially severe and/or catastrophic results. In the case of coronary vessels, however, this risk is minimal since coronary vessels rarely experience traumas transmitted from external sources.
- A second common category of stents is referred to as self-expandable stents. Self-expandable stents are generally made of shape memory materials that act like a spring. Typical metals used in this type of stent include Nitinol and 304 stainless steel. A common procedure for implanting a self-expandable stent involves a two-step process. First, the narrowed vessel is dilated with the balloon as described above. Second, the stent is implanted into the dilated vessel portion. To accomplish the stent implantation, the stent is installed on the end of a catheter in a compressed, small diameter state and is retained in the small diameter by inserting the stent into the lumen of the catheter or by other means. The stent is then guided to the balloon-dilated portion and is released from the catheter and allowed to radially spring outward to an expanded diameter until the stent contacts and presses against the vessel wall. Traditionally, self-expandable stents have been more commonly used in peripheral vessels than in coronary vessels due to the shape memory characteristic of the metals used in these stents. One advantage of self-expandable stents for peripheral vessels is that traumas from external sources do not permanently deform the stent. Instead, the stent may temporarily deform during an unusually harsh trauma but will spring back to its expanded state once the trauma is relieved. Self-expandable stents, however, are often considered to be less preferred for coronary vessels as compared to balloon-expandable stents. One reason for this is that balloon-expandable stents can be precisely sized to a particular vessel diameter and shape since the ductile metal that is used can be plastically deformed to a desired size and shape. In contrast, self-expandable stents are designed with a particular expansible range. Thus, after being installed self-expandable stents continue to exert pressure against the vessel wall.
- However, even when a stent is used in conjunction with conventional PTA procedures, restenosis still remains a problem. As discussed above, one cause of restenosis is neointimal hyperplasia which may result from damage to the vessel wall. This cause of neointimal hyperplasia remains a problem even when a stent is used. In addition, the synthetic materials that are usually used in stents may also contribute to neointimal hyperplasia. The cause of this problem is the body's tendency to grow new living tissues around and over newly implanted foreign objects. Thus, despite the mechanical support structure provided by the stent, restenosis remains a problem.
- One approach that has been offered to address the problem of restenosis has been to coat stents with drugs that are designed to inhibit cellular growth. Although many such drugs are known, common examples of these types of drugs include Paclitaxel, Sirolimus and Everolimus. However, despite the benefits of these types of drugs, numerous problems still exist with the current methods that are used to apply these and other coatings to stents.
- Typically, a stent is provided by the manufacturer as part of a pre-assembled package. For example, in the case of a balloon-expandable stent, the package may include a catheter, a balloon formed at the end of the catheter, and a drug-coated stent mounted onto the balloon. In the case of a self-expandable stent, the package may include a catheter, a mounting apparatus for retaining and releasing the stent, and a drug-coated stent mounted on the apparatus.
- One method that may be used to manufacture the above-described stent assemblies involves coating the stent first in a separate step and then mounting the coated stent onto the balloon or other mounting apparatus. Common coating processes include dipping, spraying and painting the drug onto the stent. However, these methods suffer from numerous problems. One problem is the difficulty of mounting the coated stent onto the catheter without damaging the coating that has been applied. In addition, many conventional coating processes are difficult to control and apply an uneven coating on the stent. Moreover, when the stent is coated separately, it is difficult to avoid coating at least part of both the inside and outside surfaces of the stent.
- Alternatively, the stent may be coated after being mounted onto the catheter. However, this method has not been perfected. As mentioned, conventional coating processes are difficult to control and apply uneven coatings. This can be an even more significant problem when the coating is applied to a stent mounted to a catheter since the coating inevitably ends up coating the catheter, balloon and/or mounting apparatus also.
- Precisely controlling the application of coatings on stents is important for a number of reasons. For example, in the case of drug coatings in particular, it is important to ensure that the drug is applied as evenly as possible on the specific surfaces where the coating is needed. This ensures a uniform physiological response to the drug after the stent is implanted. Another important reason for precisely controlling the application of coatings is the high cost of many coatings. Typically, in the case of drug coatings, the cost of the drug per unit volume can be very expensive. Therefore, the drug should be applied as precisely as possible to the surfaces of the stent where the effectiveness of the drug can be maximized. Thus, by minimizing waste during the coating process, the overall cost of the stent assembly may be reduced.
- It is apparent to the inventor that a stent assembly is desired in which coatings may be applied to the stent in a more effective manner than is presently possible. Accordingly, a solution is described more fully below that solves this and other problems.
- A stent assembly is provided with a conductor that is permanently affixed to a catheter. Preferably, the conductor is applied to the exterior of the catheter using conductive ink. The conductor extends longitudinally along the catheter and contacts the stent. One advantage of the conductor is that the stent assembly may be coated with drugs or other coatings using an electrostatic coating process. During the electrostatic coating process, the conductor is grounded or connected to an opposite electrical charge, thereby providing electrical attraction between charged coating particles and the stent. Additional details and advantages are further described below.
- The invention may be more fully understood by reading the following description in conjunction with the drawings in which:
-
FIG. 1 is a side view of a catheter with a balloon and stent located at a distal end thereof, showing an electrostatic coating process; and -
FIG. 2 is a close-up side view of a portion of the catheter, showing the balloon and the stent with a conductor extending along a portion thereof. - Referring now to the figures, a
stent assembly 10 is provided for use in percutaneous transluminal angioplasty (“PTA”) procedures. Thestent assembly 10 is provided as a pre-assembled package with thestent 16 mounted onto aballoon 14 which is formed at the end of acatheter 12. Although not shown, the principles taught herein may also be adapted to a self-expandable stent assembly in which the stent is mounted on a mounting apparatus that selectively retains and releases the stent. - The
catheter 12 includes aconductor 18 that is permanently affixed to thecatheter 12. As shown, theconductor 18 is affixed to the outer surface of thecatheter 12 and extends longitudinally along a portion of thecatheter 12. Theconductor 18 may extend along the full length of thecatheter 12, or theconductor 18 may extend as little as an inch or less along thecatheter 12. Theconductor 18 may also extend along a portion of theballoon 14. At one end, theconductor 18 contacts an inner surface of thestent 16. Since thestent 16 is metallic, an electrical connection is made between thestent 16 and theconductor 18. - In the preferred embodiment, the
conductor 18 comprises conductive ink that is applied to the exterior of thecatheter 12 andballoon 14 as a stripe. One type of conductive ink that may be used is a silver-based epoxy ink. Conductive ink of this type may be obtained from Creative Metals Incorporated as product number CMI 119-21 and referred to as Printable Solvent Resistant Electrically Inductive Ink. However, numerous other types of conductive ink may also be used, such as platinum-based, gold-based and copper-based inks. Non-epoxy inks may also be used, such as urethane inks. In general, any compound which may be applied in a liquid or gel form and is capable of conducting an electrical current after application may be considered conductive ink. Moreover, theconductor 18 may also comprise any other conductive material, such as conductive polymers. - The conductive ink may be applied to the
catheter 12 andballoon 14 with a variety of printing processes, such as pad printing, ink jet printing, spraying, marker striping, painting or other like processes. However, pad printing is preferred since it is relatively easy with this process to apply a consistent ink stripe on thecatheter 12 andballoon 14. - An advantage of the
conductor 18 is thatcoatings 24 may be applied to thestent 16 with electrostatic coating processes instead of conventional coating processes. As shown inFIG. 1 , anelectrostatic spray nozzle 20 charges the coating material and dispenses chargedcoating particles 22 towards and around thestent 16. Examples of electrostatic coating processes that may be used are described in U.S. Pat. Nos. 4,749,125; 5,165,601; 5,086,973 and 5,332,154, which are all hereby incorporated by reference herein. Other electrostatic coating processes may also be used, and any coating process that electrically charges the coating material may be adapted for coating thestent 16. An electrical charge is also applied to theconductor 18 by either grounding theconductor 18 or by connecting theconductor 18 to a charge that is opposite to the charge of thecoating particles 22. Thus, the charged coating particles 32 become electrically attracted to thestent 16. As a result, thecoating particles 22 are drawn to the surfaces of thestent 16 and adhere to thestent 16 once contact is made. Thecoating 24 that results is considerably more consistent and uniform than coatings applied by conventional processes. Theconductor 18 may be grounded 26 in any manner known to those in the art. For example, theconductor 18 may be grounded 26 by the fixture that holds thestent assembly 10 during the coating process. Collets or other known arrangements may be readily adapted to serve as aground 26 for theconductor 18. Likewise, theconductor 18 may be connected to an opposite charge in any manner known in the art. - Electrostatic coating offers significant improvements over conventional coating processes, such as dipping, spraying and painting. One of the benefits of electrostatic coating is that the application of the
coating 24 can be precisely controlled. Thus, in the case of drug coatings, a precise amount of the therapeutic agent can be applied uniformly over thestent 16 without the inconsistencies and waste of conventional processes. This is particularly helpful when typical anti-restenosis drugs are used since these drugs can be especially expensive.Other coatings 24 however may also be applied to thestent 16, such as hydrophilic coatings, with similar benefits. - There are also several advantages of coating the
stent 16 after thestent 16 has been mounted to thecatheter 16 as compared to separately coating thestent 16. One benefit is that damage to thecoating 24 can be minimized since the manufacturer does not need to handle an already coated stent when mounting thestent 16 to theballoon 14. Another benefit is that thecoating 24 is applied only to the outside surface of thestent 16 instead of being applied partially to the inside of thestent 16 as may occur when thestent 16 is coated separately. In the case of anti-restenosis drugs, this is a more efficient result since the anti-restenosis drug is primarily needed on the exterior surfaces of thestent 16 where thestent 16 contacts the vessel wall after implantation. Although the electrically chargedcoating particles 22 will be attracted primarily to themetallic stent 16 as compared to the non-metallic balloon, some of the drug coating 24 (or any other coating used) can be expected to pass through the openings in thestent 16 and adhere to theballoon 14 instead of thestent 16. However, even these balloon-coated portions may provide some benefits since these coated portions may contact the vessel wall during balloon expansion, thereby being transferred to the vessel wall. - A further advantage of the
conductor 18 is that it is permanently affixed to thecatheter 12. One alternative approach that could be used to electrostatically coat astent 16 involves positioning a loose ground wire under or adjacent thestent 16 to make an electrical connection. However, this approach is undesirable because the loose wire may be inadvertently left attached to thestent assembly 10 after coating. This could have serious consequences if the loose wire is not removed prior to a surgeon using thestent assembly 10 in a PTA procedure. In addition, even when the wire is properly removed during manufacturing of thestent assembly 10, the removal step could damage thestent assembly 10. One possible risk is that the wire might puncture theballoon 14. In addition, removal of the wire may dislodge some of thecoating 24. - The conductor may also provide other advantages as well. For example, the
conductor 18 may improve visualization of thecatheter 12 andstent assembly 10 during implantation by showing up more distinctly in imaging devices. Moreover, if theconductor 18 is extended along the entire longitudinal length of thecatheter 12, theconductor 18 could be used during PTA or other surgical procedures to supply electrical current to the internal area of the body that is being treated. - It is now apparent that there are many advantages of the invention provided herein. In addition to the many advantages that have been described, it is possible that there are other advantages of the invention that are not currently recognized but which may become apparent at a later time.
- While a preferred embodiment of the invention has been described, it should be understood that the invention is not so limited, and modifications may be made without departing from the invention. The scope of the invention is defined by the appended claims, and all devices that come within the meaning of the claims, either literally or by equivalence, are intended to be embraced therein.
Claims (20)
1. A stent assembly, comprising: a catheter, and a stent mounted at a distal end of said catheter, wherein said catheter comprises a conductor contacting said stent and extending longitudinally along at least a portion of said catheter, said conductor being permanently affixed to said catheter.
2. The stent assembly according to claim 1 , wherein said conductor comprises conductive ink applied to said catheter.
3. The stent assembly according to claim 2 , wherein said conductive ink is applied by pad printing.
4. The stent assembly according to claim 1 , wherein said conductor is one of silver-based, platinum-based, gold-based and copper-based.
5. The stent assembly according to claim 1 , further comprising a balloon located at said distal end of said catheter, said stent being mounted onto said balloon.
6. The stent assembly according to claim 5 , wherein said conductor extends along a portion of said balloon.
7. The stent assembly according to claim 1 , wherein said stent is metallic.
8. The stent assembly according to claim 1 , wherein said conductor contacts an inner surface of said stent.
9. The stent assembly according to claim 1 , wherein said conductor is disposed on an outer surface of said catheter.
10. The stent assembly according to claim 1 , wherein said stent is coated with an electrostatically applied coating.
11. The stent assembly according to claim 10 , wherein said coating is a drug.
12. The stent assembly according to claim 1 , further comprising a balloon located at said distal end of said catheter, said stent being mounted onto said balloon; wherein said conductor comprises conductive ink applied to said catheter; said conductor is disposed on an outer surface of said catheter; said stent is metallic; and said stent is coated with an electrostatically applied coating.
13. The stent assembly according to claim 12 , wherein said conductive ink is applied by pad printing; said conductor extends along a portion of said balloon; and said conductor contacts an inner surface of said stent.
14. The stent assembly according to claim 13 , wherein said conductor is one of silver-based, platinum-based, gold-based and copper-based, and said coating is a drug.
15. The stent assembly according to claim 1 , wherein said conductor comprises conductive ink applied to said catheter, and said conductor is disposed on an outer surface of said catheter.
16. The stent assembly according to claim 1 , further comprising a balloon located at said distal end of said catheter, said stent being mounted onto said balloon; wherein said conductor comprises conductive ink applied to said catheter; said conductor is disposed on an outer surface of said catheter; and said conductor extends along a portion of said balloon.
17. A method of coating a stent, comprising:
permanently affixing a conductor to a catheter, said conductor extending along a longitudinal portion of said catheter;
mounting a metallic stent on said catheter, wherein said metallic stent contacts said conductor;
electrically charging a coating material and dispensing said charged coating material in proximity to said metallic stent; and
applying an electrical charge to said conductor, wherein said charged coating material is attracted to said metallic stent, whereby said metallic stent is electrostatically coated with said coating material.
18. The method according to claim 17 , wherein said conductor comprises conductive ink applied to said catheter, and said conductor is disposed on an outer surface of said catheter.
19. The method according to claim 18 , wherein a balloon is located at a distal end of said catheter, said stent being mounted onto said balloon, and said conductor extends along a portion of said balloon.
20. The method according to claim 19 , wherein said conductive ink is applied by pad printing, and said conductor contacts an inner surface of said stent.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/738,812 US20050131513A1 (en) | 2003-12-16 | 2003-12-16 | Stent catheter with a permanently affixed conductor |
AU2004305488A AU2004305488B2 (en) | 2003-12-16 | 2004-10-27 | Stent catheter with a permanently affixed conductor |
PCT/US2004/035632 WO2005060870A2 (en) | 2003-12-16 | 2004-10-27 | Stent catheter with a permanently affixed conductor |
DK04796535.5T DK1699384T3 (en) | 2003-12-16 | 2004-10-27 | STENT CATS WITH A PERMANENT ESTABLISHED LEADER |
JP2006545338A JP4563402B2 (en) | 2003-12-16 | 2004-10-27 | Stent catheter with permanently attached conductor |
EP04796535.5A EP1699384B1 (en) | 2003-12-16 | 2004-10-27 | Stent catheter with a permanently affixed conductor |
CA2548761A CA2548761C (en) | 2003-12-16 | 2004-10-27 | Stent catheter with a permanently affixed conductor |
US12/013,927 US7879387B2 (en) | 2003-12-16 | 2008-01-14 | Process of electrostatically coating a stent on a catheter |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/738,812 US20050131513A1 (en) | 2003-12-16 | 2003-12-16 | Stent catheter with a permanently affixed conductor |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/013,927 Division US7879387B2 (en) | 2003-12-16 | 2008-01-14 | Process of electrostatically coating a stent on a catheter |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050131513A1 true US20050131513A1 (en) | 2005-06-16 |
Family
ID=34654264
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/738,812 Abandoned US20050131513A1 (en) | 2003-12-16 | 2003-12-16 | Stent catheter with a permanently affixed conductor |
US12/013,927 Expired - Lifetime US7879387B2 (en) | 2003-12-16 | 2008-01-14 | Process of electrostatically coating a stent on a catheter |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/013,927 Expired - Lifetime US7879387B2 (en) | 2003-12-16 | 2008-01-14 | Process of electrostatically coating a stent on a catheter |
Country Status (7)
Country | Link |
---|---|
US (2) | US20050131513A1 (en) |
EP (1) | EP1699384B1 (en) |
JP (1) | JP4563402B2 (en) |
AU (1) | AU2004305488B2 (en) |
CA (1) | CA2548761C (en) |
DK (1) | DK1699384T3 (en) |
WO (1) | WO2005060870A2 (en) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080208313A1 (en) * | 2007-02-26 | 2008-08-28 | Medtronic Vascular, Inc. | Drug Coated Stent With Magnesium Topcoat |
US20100036376A1 (en) * | 2004-08-05 | 2010-02-11 | Anderson Neil L | Process of Manufacturing a Medical Use Electrical Lead |
US20100239635A1 (en) * | 2009-03-23 | 2010-09-23 | Micell Technologies, Inc. | Drug delivery medical device |
US20110072659A1 (en) * | 2009-09-30 | 2011-03-31 | John Swanson | Medical leads with segmented electrodes and methods of fabrication thereof |
WO2012166819A1 (en) * | 2011-05-31 | 2012-12-06 | Micell Technologies, Inc. | System and process for formation of a time-released, drug-eluting transferable coating |
US8758429B2 (en) | 2005-07-15 | 2014-06-24 | Micell Technologies, Inc. | Polymer coatings containing drug powder of controlled morphology |
US8795762B2 (en) | 2010-03-26 | 2014-08-05 | Battelle Memorial Institute | System and method for enhanced electrostatic deposition and surface coatings |
US8834913B2 (en) | 2008-12-26 | 2014-09-16 | Battelle Memorial Institute | Medical implants and methods of making medical implants |
US8852625B2 (en) | 2006-04-26 | 2014-10-07 | Micell Technologies, Inc. | Coatings containing multiple drugs |
US8900651B2 (en) | 2007-05-25 | 2014-12-02 | Micell Technologies, Inc. | Polymer films for medical device coating |
US9433516B2 (en) | 2007-04-17 | 2016-09-06 | Micell Technologies, Inc. | Stents having controlled elution |
US9486431B2 (en) | 2008-07-17 | 2016-11-08 | Micell Technologies, Inc. | Drug delivery medical device |
US9510856B2 (en) | 2008-07-17 | 2016-12-06 | Micell Technologies, Inc. | Drug delivery medical device |
US9539593B2 (en) | 2006-10-23 | 2017-01-10 | Micell Technologies, Inc. | Holder for electrically charging a substrate during coating |
US9737642B2 (en) | 2007-01-08 | 2017-08-22 | Micell Technologies, Inc. | Stents having biodegradable layers |
US9789233B2 (en) | 2008-04-17 | 2017-10-17 | Micell Technologies, Inc. | Stents having bioabsorbable layers |
US9981072B2 (en) | 2009-04-01 | 2018-05-29 | Micell Technologies, Inc. | Coated stents |
US10117972B2 (en) | 2011-07-15 | 2018-11-06 | Micell Technologies, Inc. | Drug delivery medical device |
US10188772B2 (en) | 2011-10-18 | 2019-01-29 | Micell Technologies, Inc. | Drug delivery medical device |
US10232092B2 (en) | 2010-04-22 | 2019-03-19 | Micell Technologies, Inc. | Stents and other devices having extracellular matrix coating |
US10272606B2 (en) | 2013-05-15 | 2019-04-30 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
US10315217B2 (en) * | 2014-06-18 | 2019-06-11 | Kaneka Corporation | Method for manufacturing elastic tubular body |
CN109875486A (en) * | 2019-03-12 | 2019-06-14 | 刘海鹏 | A kind of visualization biliary tract sound and its application method |
US10835396B2 (en) | 2005-07-15 | 2020-11-17 | Micell Technologies, Inc. | Stent with polymer coating containing amorphous rapamycin |
US11039943B2 (en) | 2013-03-12 | 2021-06-22 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
US11369498B2 (en) | 2010-02-02 | 2022-06-28 | MT Acquisition Holdings LLC | Stent and stent delivery system with improved deliverability |
US11426494B2 (en) | 2007-01-08 | 2022-08-30 | MT Acquisition Holdings LLC | Stents having biodegradable layers |
US11904118B2 (en) | 2010-07-16 | 2024-02-20 | Micell Medtech Inc. | Drug delivery medical device |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8458879B2 (en) * | 2001-07-03 | 2013-06-11 | Advanced Bio Prosthetic Surfaces, Ltd., A Wholly Owned Subsidiary Of Palmaz Scientific, Inc. | Method of fabricating an implantable medical device |
FR2896698B1 (en) | 2006-02-02 | 2008-09-19 | Vygon Sa | NEUROSTIMULATION CATHETER AND ITS BASE |
AU2009288566A1 (en) * | 2008-08-26 | 2010-03-11 | Trutek Corp. | Electrostatically charged mask filter products and method for increased filtration efficiency |
EP3291729B1 (en) | 2015-05-07 | 2020-05-13 | Ecom Medical, Inc. | Method for fabricating invasive ecg probe |
JP7073338B2 (en) * | 2017-03-16 | 2022-05-23 | テルモ株式会社 | Balloon catheter and its manufacturing method and manufacturing equipment |
WO2020165987A1 (en) * | 2019-02-14 | 2020-08-20 | アネスト岩田株式会社 | Electrostatic spraying method and electrostatic spraying device used for electrostatic spraying method |
Citations (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3468271A (en) * | 1966-09-02 | 1969-09-23 | William Birch Eng Ltd | Sewing machines |
US4270449A (en) * | 1978-03-02 | 1981-06-02 | Toppan Printing Co., Ltd. | Method of printing plastic surfaces |
US4749125A (en) * | 1987-01-16 | 1988-06-07 | Terronics Development Corp. | Nozzle method and apparatus |
US4930494A (en) * | 1988-03-09 | 1990-06-05 | Olympus Optical Co., Ltd. | Apparatus for bending an insertion section of an endoscope using a shape memory alloy |
US5086973A (en) * | 1990-04-11 | 1992-02-11 | Terronics Development Corp. | Nozzle modulators |
US5166601A (en) * | 1990-06-28 | 1992-11-24 | U.S. Philips Corp. | Test device for electric circuits on boards |
US5332154A (en) * | 1992-02-28 | 1994-07-26 | Lundy And Associates | Shoot-up electrostatic nozzle and method |
US5431638A (en) * | 1991-04-10 | 1995-07-11 | United States Surgical Corporation | Energy dissipation device |
US5609629A (en) * | 1995-06-07 | 1997-03-11 | Med Institute, Inc. | Coated implantable medical device |
US5634476A (en) * | 1992-03-17 | 1997-06-03 | Fredric I. Orkin | Uterine contraction sensing device and method for manufacture and use thereof |
US5681308A (en) * | 1994-06-24 | 1997-10-28 | Stuart D. Edwards | Ablation apparatus for cardiac chambers |
US5807306A (en) * | 1992-11-09 | 1998-09-15 | Cortrak Medical, Inc. | Polymer matrix drug delivery apparatus |
US5938623A (en) * | 1994-10-28 | 1999-08-17 | Intella Interventional Systems | Guide wire with adjustable stiffness |
US5944710A (en) * | 1996-06-24 | 1999-08-31 | Genetronics, Inc. | Electroporation-mediated intravascular delivery |
US6032061A (en) * | 1997-02-20 | 2000-02-29 | Boston Scientifc Corporation | Catheter carrying an electrode and methods of assembly |
US6091980A (en) * | 1998-05-12 | 2000-07-18 | Massachusetts Institute Of Technology | Stent slip sensing system and method |
US6156028A (en) * | 1994-03-21 | 2000-12-05 | Prescott; Marvin A. | Method and apparatus for therapeutic laser treatment of wounds |
US6245020B1 (en) * | 1998-01-26 | 2001-06-12 | Scimed Life System, Inc. | Catheter assembly with distal end inductive coupler and embedded transmission line |
US6256525B1 (en) * | 1998-02-27 | 2001-07-03 | Ep Technologies, Inc. | Catheter distal end assemblies with bonded surface coatings |
US6299604B1 (en) * | 1998-08-20 | 2001-10-09 | Cook Incorporated | Coated implantable medical device |
US20010032013A1 (en) * | 1999-11-19 | 2001-10-18 | Denes Marton | Self-supporting laminated films, structural materials and medical devices manufactured therefrom and method of making same |
US6308097B1 (en) * | 1994-10-24 | 2001-10-23 | Transscan Medical Ltd. | Tissue characterization based on impedance images and on impedance measurements |
US6347247B1 (en) * | 1998-05-08 | 2002-02-12 | Genetronics Inc. | Electrically induced vessel vasodilation |
US20020026236A1 (en) * | 2000-01-25 | 2002-02-28 | Helmus Michael N. | Delivery systems for periadventitial delivery for treatment of restenosis and anastomotic intimal hyperplasia |
US6355058B1 (en) * | 1999-12-30 | 2002-03-12 | Advanced Cardiovascular Systems, Inc. | Stent with radiopaque coating consisting of particles in a binder |
US6356779B1 (en) * | 1999-06-04 | 2002-03-12 | 3M Innovative Properties Company | Universally functional biomedical electrode |
US6357447B1 (en) * | 1993-10-15 | 2002-03-19 | Ep Technologies, Inc. | Surface coatings for catheters, direct contacting diagnostic and therapeutic devices |
US6364902B1 (en) * | 1998-10-05 | 2002-04-02 | Noble-Met, Ltd. | Metal composite tube for biomedical applications |
US6368658B1 (en) * | 1999-04-19 | 2002-04-09 | Scimed Life Systems, Inc. | Coating medical devices using air suspension |
US20020045668A1 (en) * | 2000-07-17 | 2002-04-18 | Wenbin Dang | Compositions for sustained release of analgesic agents, and methods of making and using the same |
US6394949B1 (en) * | 1998-10-05 | 2002-05-28 | Scimed Life Systems, Inc. | Large area thermal ablation |
US6409716B1 (en) * | 1989-12-15 | 2002-06-25 | Scimed Life Systems, Inc. | Drug delivery |
US6416505B1 (en) * | 1998-05-05 | 2002-07-09 | Scimed Life Systems, Inc. | Surgical method and apparatus for positioning a diagnostic or therapeutic element within the body and pressure application probe for use with same |
US6421556B2 (en) * | 1995-07-28 | 2002-07-16 | Scimed Life Systems, Inc. | Systems and methods for conducting electrophysiological testing using high-voltage energy pulses to stun tissue |
US20020103445A1 (en) * | 2000-08-24 | 2002-08-01 | Rahdert David A. | Thermography catheter with flexible circuit temperature sensors |
US6428537B1 (en) * | 1998-05-22 | 2002-08-06 | Scimed Life Systems, Inc. | Electrophysiological treatment methods and apparatus employing high voltage pulse to render tissue temporarily unresponsive |
US6440488B2 (en) * | 1999-12-03 | 2002-08-27 | Ep Medsystems, Inc. | Flexible electrode catheter and process for manufacturing the same |
US20020128640A1 (en) * | 2001-03-07 | 2002-09-12 | Scimed Life Systems, Inc. | Internal indifferent electrode device for use with lesion creation apparatus and method of forming lesions using the same |
US20020133224A1 (en) * | 2001-03-13 | 2002-09-19 | Clara Bajgar | Drug eluting encapsulated stent |
US6463323B1 (en) * | 1998-11-12 | 2002-10-08 | Em Vascular, Inc. | Electrically mediated angiogenesis |
US6468272B1 (en) * | 1997-10-10 | 2002-10-22 | Scimed Life Systems, Inc. | Surgical probe for supporting diagnostic and therapeutic elements in contact with tissue in or around body orifices |
US20020172829A1 (en) * | 1997-02-28 | 2002-11-21 | Yuichi Mori | Coating composition, coating product and coating method |
US20020177899A1 (en) * | 1999-11-03 | 2002-11-28 | Eum Jay J. | Method of loading a stent on a delivery catheter |
US20020188324A1 (en) * | 2001-05-11 | 2002-12-12 | Blinn Stephen M. | Method and system for improving the effectiveness of medical devices by adhering drugs to the surface thereof |
US6500144B1 (en) * | 2000-09-15 | 2002-12-31 | Scimed Life Systems, Inc. | Steerable catheter and self-mounting center support for use with same |
US20030003221A1 (en) * | 2001-07-02 | 2003-01-02 | Zhong Sheng-Ping (Samuel) | Coating dispensing system and method using a solenoid head for coating medical devices |
US20030018381A1 (en) * | 2000-01-25 | 2003-01-23 | Scimed Life Systems, Inc. | Manufacturing medical devices by vapor deposition |
US6511478B1 (en) * | 2000-06-30 | 2003-01-28 | Scimed Life Systems, Inc. | Medical probe with reduced number of temperature sensor wires |
US6529756B1 (en) * | 1999-11-22 | 2003-03-04 | Scimed Life Systems, Inc. | Apparatus for mapping and coagulating soft tissue in or around body orifices |
US20030054090A1 (en) * | 2001-09-18 | 2003-03-20 | Henrik Hansen | Method for spray-coating medical devices |
US6537310B1 (en) * | 1999-11-19 | 2003-03-25 | Advanced Bio Prosthetic Surfaces, Ltd. | Endoluminal implantable devices and method of making same |
US6575966B2 (en) * | 1999-08-23 | 2003-06-10 | Cryocath Technologies Inc. | Endovascular cryotreatment catheter |
US6579690B1 (en) * | 1997-12-05 | 2003-06-17 | Therasense, Inc. | Blood analyte monitoring through subcutaneous measurement |
US6589546B2 (en) * | 1998-08-28 | 2003-07-08 | Scimed Life Systems, Inc. | Polymeric coatings for controlled delivery of active agents |
US20030130615A1 (en) * | 2000-03-23 | 2003-07-10 | Scimed Life Systems, Inc. | Pressure sensor for therapeutic delivery device and method |
US6596699B2 (en) * | 1998-09-22 | 2003-07-22 | Biosurface Engineering Technologies, Inc. | Nucleic acid coating compositions and methods |
US6607598B2 (en) * | 1999-04-19 | 2003-08-19 | Scimed Life Systems, Inc. | Device for protecting medical devices during a coating process |
US20030158548A1 (en) * | 2002-02-19 | 2003-08-21 | Phan Huy D. | Surgical system including clamp and apparatus for securing an energy transmission device to the clamp and method of converting a clamp into an electrophysiology device |
US6610055B1 (en) * | 1997-10-10 | 2003-08-26 | Scimed Life Systems, Inc. | Surgical method for positioning a diagnostic or therapeutic element on the epicardium or other organ surface |
US6613046B1 (en) * | 1999-11-22 | 2003-09-02 | Scimed Life Systems, Inc. | Loop structures for supporting diagnostic and therapeutic elements in contact with body tissue |
US20030185964A1 (en) * | 2002-03-28 | 2003-10-02 | Jan Weber | Method for spray-coating a medical device having a tubular wall such as a stent |
US20030204238A1 (en) * | 2002-04-26 | 2003-10-30 | Eugene Tedeschi | Coated stent with crimpable coating |
US6749628B1 (en) * | 2001-05-17 | 2004-06-15 | Advanced Cardiovascular Systems, Inc. | Stent and catheter assembly and method for treating bifurcations |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2555393B2 (en) * | 1988-01-08 | 1996-11-20 | 勝史 吉田 | Stenosis vessel treatment tool |
US5304121A (en) * | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
US5165601A (en) * | 1990-04-11 | 1992-11-24 | Terronics Development Corporation | Nozzle for low resistivity flowable material |
US5305320A (en) | 1992-10-06 | 1994-04-19 | At&T Bell Laboratories | Peripheral communications network |
GB9616267D0 (en) | 1996-08-02 | 1996-09-11 | Ranier Ltd | Balloon catheter |
EP1003080B1 (en) * | 1998-11-18 | 2008-01-30 | Canon Kabushiki Kaisha | Toner, and process for producing toner |
US6648879B2 (en) * | 1999-02-24 | 2003-11-18 | Cryovascular Systems, Inc. | Safety cryotherapy catheter |
US6468271B1 (en) | 1999-02-24 | 2002-10-22 | Scimed Life Systems, Inc. | Device and method for percutaneous myocardial revascularization |
US6364903B2 (en) | 1999-03-19 | 2002-04-02 | Meadox Medicals, Inc. | Polymer coated stent |
US6786889B1 (en) | 1999-03-31 | 2004-09-07 | Scimed Life Systems, Inc | Textured and/or marked balloon for stent delivery |
EP1190252B1 (en) | 1999-04-28 | 2008-12-31 | Eidgenössische Technische Hochschule Zürich | Polyionic coatings in analytic and sensor devices |
GB9920112D0 (en) * | 1999-08-26 | 1999-10-27 | Aortech Int Plc | Improvements relating to catheters (I) |
JP2002345972A (en) * | 2001-05-30 | 2002-12-03 | Kaneka Medix Corp | Stent and method of manufacturing for the same |
-
2003
- 2003-12-16 US US10/738,812 patent/US20050131513A1/en not_active Abandoned
-
2004
- 2004-10-27 JP JP2006545338A patent/JP4563402B2/en active Active
- 2004-10-27 CA CA2548761A patent/CA2548761C/en active Active
- 2004-10-27 WO PCT/US2004/035632 patent/WO2005060870A2/en active Application Filing
- 2004-10-27 DK DK04796535.5T patent/DK1699384T3/en active
- 2004-10-27 AU AU2004305488A patent/AU2004305488B2/en active Active
- 2004-10-27 EP EP04796535.5A patent/EP1699384B1/en active Active
-
2008
- 2008-01-14 US US12/013,927 patent/US7879387B2/en not_active Expired - Lifetime
Patent Citations (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3468271A (en) * | 1966-09-02 | 1969-09-23 | William Birch Eng Ltd | Sewing machines |
US4270449A (en) * | 1978-03-02 | 1981-06-02 | Toppan Printing Co., Ltd. | Method of printing plastic surfaces |
US4749125A (en) * | 1987-01-16 | 1988-06-07 | Terronics Development Corp. | Nozzle method and apparatus |
US4930494A (en) * | 1988-03-09 | 1990-06-05 | Olympus Optical Co., Ltd. | Apparatus for bending an insertion section of an endoscope using a shape memory alloy |
US6409716B1 (en) * | 1989-12-15 | 2002-06-25 | Scimed Life Systems, Inc. | Drug delivery |
US5086973A (en) * | 1990-04-11 | 1992-02-11 | Terronics Development Corp. | Nozzle modulators |
US5166601A (en) * | 1990-06-28 | 1992-11-24 | U.S. Philips Corp. | Test device for electric circuits on boards |
US5431638A (en) * | 1991-04-10 | 1995-07-11 | United States Surgical Corporation | Energy dissipation device |
US5332154A (en) * | 1992-02-28 | 1994-07-26 | Lundy And Associates | Shoot-up electrostatic nozzle and method |
US5634476A (en) * | 1992-03-17 | 1997-06-03 | Fredric I. Orkin | Uterine contraction sensing device and method for manufacture and use thereof |
US5807306A (en) * | 1992-11-09 | 1998-09-15 | Cortrak Medical, Inc. | Polymer matrix drug delivery apparatus |
US6357447B1 (en) * | 1993-10-15 | 2002-03-19 | Ep Technologies, Inc. | Surface coatings for catheters, direct contacting diagnostic and therapeutic devices |
US6156028A (en) * | 1994-03-21 | 2000-12-05 | Prescott; Marvin A. | Method and apparatus for therapeutic laser treatment of wounds |
US5681308A (en) * | 1994-06-24 | 1997-10-28 | Stuart D. Edwards | Ablation apparatus for cardiac chambers |
US6308097B1 (en) * | 1994-10-24 | 2001-10-23 | Transscan Medical Ltd. | Tissue characterization based on impedance images and on impedance measurements |
US5938623A (en) * | 1994-10-28 | 1999-08-17 | Intella Interventional Systems | Guide wire with adjustable stiffness |
US6096070A (en) * | 1995-06-07 | 2000-08-01 | Med Institute Inc. | Coated implantable medical device |
US5609629A (en) * | 1995-06-07 | 1997-03-11 | Med Institute, Inc. | Coated implantable medical device |
US6421556B2 (en) * | 1995-07-28 | 2002-07-16 | Scimed Life Systems, Inc. | Systems and methods for conducting electrophysiological testing using high-voltage energy pulses to stun tissue |
US5944710A (en) * | 1996-06-24 | 1999-08-31 | Genetronics, Inc. | Electroporation-mediated intravascular delivery |
US6032061A (en) * | 1997-02-20 | 2000-02-29 | Boston Scientifc Corporation | Catheter carrying an electrode and methods of assembly |
US20020172829A1 (en) * | 1997-02-28 | 2002-11-21 | Yuichi Mori | Coating composition, coating product and coating method |
US6468272B1 (en) * | 1997-10-10 | 2002-10-22 | Scimed Life Systems, Inc. | Surgical probe for supporting diagnostic and therapeutic elements in contact with tissue in or around body orifices |
US6610055B1 (en) * | 1997-10-10 | 2003-08-26 | Scimed Life Systems, Inc. | Surgical method for positioning a diagnostic or therapeutic element on the epicardium or other organ surface |
US6579690B1 (en) * | 1997-12-05 | 2003-06-17 | Therasense, Inc. | Blood analyte monitoring through subcutaneous measurement |
US6450965B2 (en) * | 1998-01-26 | 2002-09-17 | Scimed Life Systems, Inc. | Imaging catheter assembly with distal end inductive coupler and embedded transmission line |
US6245020B1 (en) * | 1998-01-26 | 2001-06-12 | Scimed Life System, Inc. | Catheter assembly with distal end inductive coupler and embedded transmission line |
US6256525B1 (en) * | 1998-02-27 | 2001-07-03 | Ep Technologies, Inc. | Catheter distal end assemblies with bonded surface coatings |
US6416505B1 (en) * | 1998-05-05 | 2002-07-09 | Scimed Life Systems, Inc. | Surgical method and apparatus for positioning a diagnostic or therapeutic element within the body and pressure application probe for use with same |
US6347247B1 (en) * | 1998-05-08 | 2002-02-12 | Genetronics Inc. | Electrically induced vessel vasodilation |
US6091980A (en) * | 1998-05-12 | 2000-07-18 | Massachusetts Institute Of Technology | Stent slip sensing system and method |
US6428537B1 (en) * | 1998-05-22 | 2002-08-06 | Scimed Life Systems, Inc. | Electrophysiological treatment methods and apparatus employing high voltage pulse to render tissue temporarily unresponsive |
US6299604B1 (en) * | 1998-08-20 | 2001-10-09 | Cook Incorporated | Coated implantable medical device |
US6589546B2 (en) * | 1998-08-28 | 2003-07-08 | Scimed Life Systems, Inc. | Polymeric coatings for controlled delivery of active agents |
US6596699B2 (en) * | 1998-09-22 | 2003-07-22 | Biosurface Engineering Technologies, Inc. | Nucleic acid coating compositions and methods |
US6394949B1 (en) * | 1998-10-05 | 2002-05-28 | Scimed Life Systems, Inc. | Large area thermal ablation |
US6364902B1 (en) * | 1998-10-05 | 2002-04-02 | Noble-Met, Ltd. | Metal composite tube for biomedical applications |
US6463323B1 (en) * | 1998-11-12 | 2002-10-08 | Em Vascular, Inc. | Electrically mediated angiogenesis |
US6607598B2 (en) * | 1999-04-19 | 2003-08-19 | Scimed Life Systems, Inc. | Device for protecting medical devices during a coating process |
US6368658B1 (en) * | 1999-04-19 | 2002-04-09 | Scimed Life Systems, Inc. | Coating medical devices using air suspension |
US6356779B1 (en) * | 1999-06-04 | 2002-03-12 | 3M Innovative Properties Company | Universally functional biomedical electrode |
US6575966B2 (en) * | 1999-08-23 | 2003-06-10 | Cryocath Technologies Inc. | Endovascular cryotreatment catheter |
US20020177899A1 (en) * | 1999-11-03 | 2002-11-28 | Eum Jay J. | Method of loading a stent on a delivery catheter |
US20010032013A1 (en) * | 1999-11-19 | 2001-10-18 | Denes Marton | Self-supporting laminated films, structural materials and medical devices manufactured therefrom and method of making same |
US6537310B1 (en) * | 1999-11-19 | 2003-03-25 | Advanced Bio Prosthetic Surfaces, Ltd. | Endoluminal implantable devices and method of making same |
US6529756B1 (en) * | 1999-11-22 | 2003-03-04 | Scimed Life Systems, Inc. | Apparatus for mapping and coagulating soft tissue in or around body orifices |
US6613046B1 (en) * | 1999-11-22 | 2003-09-02 | Scimed Life Systems, Inc. | Loop structures for supporting diagnostic and therapeutic elements in contact with body tissue |
US6440488B2 (en) * | 1999-12-03 | 2002-08-27 | Ep Medsystems, Inc. | Flexible electrode catheter and process for manufacturing the same |
US6355058B1 (en) * | 1999-12-30 | 2002-03-12 | Advanced Cardiovascular Systems, Inc. | Stent with radiopaque coating consisting of particles in a binder |
US20030018381A1 (en) * | 2000-01-25 | 2003-01-23 | Scimed Life Systems, Inc. | Manufacturing medical devices by vapor deposition |
US20020026236A1 (en) * | 2000-01-25 | 2002-02-28 | Helmus Michael N. | Delivery systems for periadventitial delivery for treatment of restenosis and anastomotic intimal hyperplasia |
US20030130615A1 (en) * | 2000-03-23 | 2003-07-10 | Scimed Life Systems, Inc. | Pressure sensor for therapeutic delivery device and method |
US6511478B1 (en) * | 2000-06-30 | 2003-01-28 | Scimed Life Systems, Inc. | Medical probe with reduced number of temperature sensor wires |
US20020045668A1 (en) * | 2000-07-17 | 2002-04-18 | Wenbin Dang | Compositions for sustained release of analgesic agents, and methods of making and using the same |
US20020103445A1 (en) * | 2000-08-24 | 2002-08-01 | Rahdert David A. | Thermography catheter with flexible circuit temperature sensors |
US6500144B1 (en) * | 2000-09-15 | 2002-12-31 | Scimed Life Systems, Inc. | Steerable catheter and self-mounting center support for use with same |
US20020128640A1 (en) * | 2001-03-07 | 2002-09-12 | Scimed Life Systems, Inc. | Internal indifferent electrode device for use with lesion creation apparatus and method of forming lesions using the same |
US20020133224A1 (en) * | 2001-03-13 | 2002-09-19 | Clara Bajgar | Drug eluting encapsulated stent |
US20020188324A1 (en) * | 2001-05-11 | 2002-12-12 | Blinn Stephen M. | Method and system for improving the effectiveness of medical devices by adhering drugs to the surface thereof |
US6749628B1 (en) * | 2001-05-17 | 2004-06-15 | Advanced Cardiovascular Systems, Inc. | Stent and catheter assembly and method for treating bifurcations |
US20030003221A1 (en) * | 2001-07-02 | 2003-01-02 | Zhong Sheng-Ping (Samuel) | Coating dispensing system and method using a solenoid head for coating medical devices |
US20030054090A1 (en) * | 2001-09-18 | 2003-03-20 | Henrik Hansen | Method for spray-coating medical devices |
US20030158548A1 (en) * | 2002-02-19 | 2003-08-21 | Phan Huy D. | Surgical system including clamp and apparatus for securing an energy transmission device to the clamp and method of converting a clamp into an electrophysiology device |
US20030185964A1 (en) * | 2002-03-28 | 2003-10-02 | Jan Weber | Method for spray-coating a medical device having a tubular wall such as a stent |
US20030204238A1 (en) * | 2002-04-26 | 2003-10-30 | Eugene Tedeschi | Coated stent with crimpable coating |
Cited By (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8286338B2 (en) * | 2004-08-05 | 2012-10-16 | Cathrx Ltd | Process of manufacturing a medical use electrical lead |
US20100036376A1 (en) * | 2004-08-05 | 2010-02-11 | Anderson Neil L | Process of Manufacturing a Medical Use Electrical Lead |
US10668275B2 (en) | 2004-08-05 | 2020-06-02 | Cathrx Ltd | Electrical leads for medical use |
US10898353B2 (en) | 2005-07-15 | 2021-01-26 | Micell Technologies, Inc. | Polymer coatings containing drug powder of controlled morphology |
US9827117B2 (en) | 2005-07-15 | 2017-11-28 | Micell Technologies, Inc. | Polymer coatings containing drug powder of controlled morphology |
US8758429B2 (en) | 2005-07-15 | 2014-06-24 | Micell Technologies, Inc. | Polymer coatings containing drug powder of controlled morphology |
US10835396B2 (en) | 2005-07-15 | 2020-11-17 | Micell Technologies, Inc. | Stent with polymer coating containing amorphous rapamycin |
US11911301B2 (en) | 2005-07-15 | 2024-02-27 | Micell Medtech Inc. | Polymer coatings containing drug powder of controlled morphology |
US9737645B2 (en) | 2006-04-26 | 2017-08-22 | Micell Technologies, Inc. | Coatings containing multiple drugs |
US11850333B2 (en) | 2006-04-26 | 2023-12-26 | Micell Medtech Inc. | Coatings containing multiple drugs |
US11007307B2 (en) | 2006-04-26 | 2021-05-18 | Micell Technologies, Inc. | Coatings containing multiple drugs |
US9415142B2 (en) | 2006-04-26 | 2016-08-16 | Micell Technologies, Inc. | Coatings containing multiple drugs |
US8852625B2 (en) | 2006-04-26 | 2014-10-07 | Micell Technologies, Inc. | Coatings containing multiple drugs |
US9539593B2 (en) | 2006-10-23 | 2017-01-10 | Micell Technologies, Inc. | Holder for electrically charging a substrate during coating |
US11426494B2 (en) | 2007-01-08 | 2022-08-30 | MT Acquisition Holdings LLC | Stents having biodegradable layers |
US9737642B2 (en) | 2007-01-08 | 2017-08-22 | Micell Technologies, Inc. | Stents having biodegradable layers |
US10617795B2 (en) | 2007-01-08 | 2020-04-14 | Micell Technologies, Inc. | Stents having biodegradable layers |
US8273402B2 (en) * | 2007-02-26 | 2012-09-25 | Medtronic Vascular, Inc. | Drug coated stent with magnesium topcoat |
US20080208313A1 (en) * | 2007-02-26 | 2008-08-28 | Medtronic Vascular, Inc. | Drug Coated Stent With Magnesium Topcoat |
US9486338B2 (en) | 2007-04-17 | 2016-11-08 | Micell Technologies, Inc. | Stents having controlled elution |
US9433516B2 (en) | 2007-04-17 | 2016-09-06 | Micell Technologies, Inc. | Stents having controlled elution |
US9775729B2 (en) | 2007-04-17 | 2017-10-03 | Micell Technologies, Inc. | Stents having controlled elution |
US8900651B2 (en) | 2007-05-25 | 2014-12-02 | Micell Technologies, Inc. | Polymer films for medical device coating |
US10350333B2 (en) | 2008-04-17 | 2019-07-16 | Micell Technologies, Inc. | Stents having bioabsorable layers |
US9789233B2 (en) | 2008-04-17 | 2017-10-17 | Micell Technologies, Inc. | Stents having bioabsorbable layers |
US9510856B2 (en) | 2008-07-17 | 2016-12-06 | Micell Technologies, Inc. | Drug delivery medical device |
US9486431B2 (en) | 2008-07-17 | 2016-11-08 | Micell Technologies, Inc. | Drug delivery medical device |
US9981071B2 (en) | 2008-07-17 | 2018-05-29 | Micell Technologies, Inc. | Drug delivery medical device |
US10350391B2 (en) | 2008-07-17 | 2019-07-16 | Micell Technologies, Inc. | Drug delivery medical device |
US8834913B2 (en) | 2008-12-26 | 2014-09-16 | Battelle Memorial Institute | Medical implants and methods of making medical implants |
US20100239635A1 (en) * | 2009-03-23 | 2010-09-23 | Micell Technologies, Inc. | Drug delivery medical device |
US9981072B2 (en) | 2009-04-01 | 2018-05-29 | Micell Technologies, Inc. | Coated stents |
US10653820B2 (en) | 2009-04-01 | 2020-05-19 | Micell Technologies, Inc. | Coated stents |
US8925191B2 (en) | 2009-09-30 | 2015-01-06 | Advanced Neuromodulation Systems, Inc. | Method of fabricating a stimulation lead |
US8171621B2 (en) * | 2009-09-30 | 2012-05-08 | Advanced Neuromodulation Systems, Inc. | Methods of fabrication of a simulation lead |
US20110072659A1 (en) * | 2009-09-30 | 2011-03-31 | John Swanson | Medical leads with segmented electrodes and methods of fabrication thereof |
US11369498B2 (en) | 2010-02-02 | 2022-06-28 | MT Acquisition Holdings LLC | Stent and stent delivery system with improved deliverability |
US9687864B2 (en) | 2010-03-26 | 2017-06-27 | Battelle Memorial Institute | System and method for enhanced electrostatic deposition and surface coatings |
US8795762B2 (en) | 2010-03-26 | 2014-08-05 | Battelle Memorial Institute | System and method for enhanced electrostatic deposition and surface coatings |
US10232092B2 (en) | 2010-04-22 | 2019-03-19 | Micell Technologies, Inc. | Stents and other devices having extracellular matrix coating |
US11904118B2 (en) | 2010-07-16 | 2024-02-20 | Micell Medtech Inc. | Drug delivery medical device |
US10464100B2 (en) | 2011-05-31 | 2019-11-05 | Micell Technologies, Inc. | System and process for formation of a time-released, drug-eluting transferable coating |
WO2012166819A1 (en) * | 2011-05-31 | 2012-12-06 | Micell Technologies, Inc. | System and process for formation of a time-released, drug-eluting transferable coating |
US10117972B2 (en) | 2011-07-15 | 2018-11-06 | Micell Technologies, Inc. | Drug delivery medical device |
US10729819B2 (en) | 2011-07-15 | 2020-08-04 | Micell Technologies, Inc. | Drug delivery medical device |
US10188772B2 (en) | 2011-10-18 | 2019-01-29 | Micell Technologies, Inc. | Drug delivery medical device |
US11039943B2 (en) | 2013-03-12 | 2021-06-22 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
US10272606B2 (en) | 2013-05-15 | 2019-04-30 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
US10315217B2 (en) * | 2014-06-18 | 2019-06-11 | Kaneka Corporation | Method for manufacturing elastic tubular body |
CN109875486A (en) * | 2019-03-12 | 2019-06-14 | 刘海鹏 | A kind of visualization biliary tract sound and its application method |
Also Published As
Publication number | Publication date |
---|---|
CA2548761A1 (en) | 2005-07-07 |
EP1699384B1 (en) | 2015-05-06 |
JP2007534362A (en) | 2007-11-29 |
JP4563402B2 (en) | 2010-10-13 |
AU2004305488B2 (en) | 2010-09-30 |
WO2005060870A2 (en) | 2005-07-07 |
EP1699384A2 (en) | 2006-09-13 |
WO2005060870A3 (en) | 2005-12-08 |
CA2548761C (en) | 2012-05-15 |
DK1699384T3 (en) | 2015-07-27 |
US7879387B2 (en) | 2011-02-01 |
US20080113084A1 (en) | 2008-05-15 |
AU2004305488A1 (en) | 2005-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7879387B2 (en) | Process of electrostatically coating a stent on a catheter | |
JP4344384B2 (en) | Method and system for treating side branch ostium | |
US20040230176A1 (en) | System for treating a vascular condition that inhibits restenosis at stent ends | |
US7861570B2 (en) | Stent with improved drug loading capacity | |
US7208008B2 (en) | Balloonless direct stenting device | |
US7470281B2 (en) | Coated stent with crimpable coating | |
EP1534181B1 (en) | Centering catheter | |
JP4394461B2 (en) | Overlapping covered stent | |
EP1755485B1 (en) | Method and system for stent retention using an adhesive | |
EP2234664B1 (en) | Methods for incorporating a drug into an elastomeric medical device | |
US20030139801A1 (en) | Delivery of therapeutic capable agents | |
US20040147998A1 (en) | Differentially coated stent | |
US20060155370A1 (en) | Stent with intermittent coating | |
EP1680153B1 (en) | Natural tissue stent | |
US20050182474A1 (en) | Coated stent having protruding crowns and elongated struts | |
WO2012132801A1 (en) | Stent and stent delivery system | |
US20040215314A1 (en) | Stent deployment assembly with collars for drug-eluting stent | |
US10076426B2 (en) | Stent and stent delivery system | |
WO2021035683A1 (en) | Balloon stent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: COOK INCORPORATED, INDIANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MYERS, RANDY JOE;REEL/FRAME:014823/0871 Effective date: 20031119 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |